Osanetant
Osanetant Uses, Dosage, Side Effects, Food Interaction and all others data.
Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System (CNS) disorders. In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. This follows an earlier decision to discontinue development of eplivanserin for schizophrenia.
Osanetant is a neurokinin-3 (NK3) receptor antagonist. Preliminary clinical trials have demonstrated that osanetant is superior to placebo on global assessment of efficacy and measures of positive symptoms in schizophrenia.
| Trade Name | Osanetant |
| Generic | Osanetant |
| Osanetant Other Names | Osanetant |
| Type | |
| Formula | C35H41Cl2N3O2 |
| Weight | Average: 606.625 Monoisotopic: 605.257582985 |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
Potential therapy for schizophrenia, depression and visceral pain.
How Osanetant works
The mechanism of action of osanetant is uncertain at this point. Various preclinical data indicate that activation of NK3 receptors enhances the release of biogenic amines, including dopamine and serotonin. NK3 receptor antagonists could block NK3-receptor-mediated activation of these systems.
Innovators Monograph
You find simplified version here Osanetant
